Skip to main content

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

Volunteers Needed for Lupus Research Study

a woman holding up a ribbon

The role of Anifrolumab in improving blood vessel function in people with lupus

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and damage in the affected organs including blood vessels. People with lupus that get proper medical care, preventive care, and education can significantly improve function and quality of life. Researchers at NIH are testing a drug (anifrolumab) to see if this can improve blood vessel function and reduce blood vessel inflammation in people with SLE.

You can participate if you are:

  • 18 to 80 years old with SLE
  • Not pregnant or breastfeeding

Study Design:

  • This study requires nine visits within eight months
  • Will receive Anifrolumab once every four weeks
  • Physical examination and questionnaires
  • Electrocardiogram (EKG), chest radiographs, PET/CT imaging
  • You will need to provide blood and urine samples

Study procedures and medications are provided at no cost. Travel costs for study visits will be reimbursed in accordance with NIH guidelines.

The NIH Clinical Center, America's Research Hospital is located in Bethesda, MD on the Metro red line (Medical Center stop).

For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov

Or go online:
bit.ly/3gnFue7
Refer to NIH study # 000682-AR

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)